AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
AbbVie Acquires Capstan Therapeutics for Up to $2.1B to Enhance Immunology Portfolio
ByAinvest
Wednesday, Aug 20, 2025 2:50 am ET1min read
AbbVie has completed its acquisition of clinical-stage biotech Capstan Therapeutics for up to $2.1B. The deal includes Capstan's lead asset, CPTX2309, a targeted lipid nanoparticle, anti-CD19 CAR-T therapy for B cell-mediated autoimmune diseases in phase 1. The acquisition is expected to strengthen AbbVie's immunology portfolio.
AbbVie Inc. (NYSE: ABBV) has completed its acquisition of Capstan Therapeutics, a clinical-stage biotechnology company, for up to $2.1 billion. The acquisition includes Capstan's lead asset, CPTX2309, a targeted lipid nanoparticle (tLNP) anti-CD19 CAR-T therapy candidate for B cell-mediated autoimmune diseases in Phase 1 clinical trials [2].The deal is expected to strengthen AbbVie's immunology portfolio, particularly in the CAR-T cell therapy space. CPTX2309 is a tLNP that generates CD19-specific, CD8+ in vivo CAR-T cells, designed to achieve rapid and deep B cell depletion with the aim of achieving durable, drug-free remission. This can be accomplished without the need for lymphodepleting chemotherapy, while also avoiding other challenges associated with conventional ex vivo CAR-T therapies [2].
"With the acquisition now complete, we are excited to work together with the talented team at Capstan to advance our mission of transforming patient care," said Jonathon Sedgwick, Ph.D., senior vice president and global head of discovery research, AbbVie [2].
Capstan's proprietary tLNP platform, designed to deliver RNA payloads, such as mRNA, capable of engineering specific cell types in vivo, will also be integrated into AbbVie's portfolio. This technology could enable broader applications of Capstan's platform for in vivo programming of cells [2].
The acquisition is part of AbbVie's ongoing strategy to expand its pipeline and strengthen its position in immunology. The deal also highlights AbbVie's commitment to investing in innovative therapies that address serious health issues [2].
References:
[1] https://rapport.racap.com/all-stories/capstan-abbvie-car-t-pioneer
[2] https://finance.yahoo.com/news/abbvie-completes-acquisition-capstan-therapeutics-125500277.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet